close
Trend Chart On Innovative Bioindustries September 2020, 17th
News

Trend Chart On Innovative Bioindustries September 2020, 17th

Trend Chart On Innovative Bioindustries
September 2020, 17th

FEATURE STORY

●  Nonclinical studies that support viral vector-delivered gene therapies: An EFPIA Gene Therapy Working Group perspective

BASIC SCIENCE

● Paving the road for RNA therapeutics

CLINICAL TRIALS/DATAS

● Akcea: Positive phase 2 clinical data of Vupanorsen
● The NEJM publishes study results evaluating Ionis antisense therapy
in treatment of patients with hereditary angioedema
● Bluebird Bio presents new clinical results with elivaldogene autotemcell
(eli-cel, Lenti-D™) gene therapy for Cerebral Adrenoleukodystrophy (CALD)

INDUSTRIAL LANDSCAPE & AGREEMENTS

● CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen
● CANbridge starts neuromuscular gene therapy program with UMass
● LNC Therapeutics receives FDA IND to initiate a phase 1 trial to evaluate Xla1 for the treatment of obesity and metabolic diiseases

MISCELLANEOUS

● ICER to assess CAR-T cell therapies for multiple myeloma
● Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer

Click here to view the newsletter and then click on “full screen” for an optimal reading

 

 

 

 

 


COMMENTS ARE OFF THIS POST